Research
Hormonal
Semaglutide 2.4 mg once weekly is the preferred first-line anti-obesity medication for individuals with obesity and chronic kidney disease (CKD), including non-diabetic populations, due to significant reductions in renal endpoint progression.
If you have obesity and chronic kidney disease, semaglutide 2.4 mg once weekly is the preferred first-line treatment to significantly slow kidney function decline and reduce the risk of needing dialysis or kidney replacement therapy, even if you do not have diabetes.
StrongSupportsVERY_HIGH confidence
Semaglutide should be preferred as first-line AOM in people with obesity and CKD, including non-diabetic populations, based on renal and CV outcome data. In the SELECT trial, semaglutide 2.4 mg reduced a composite renal endpoint (≥ 50% eGFR decline, macroalbuminuria onset, or need for renal replacement therapy) by 22% vs. placebo [17].
Why this rating
Based on a large, phase III randomized controlled trial (SELECT) with prespecified renal endpoints.
Source
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Dario Tuccinardi et al. · Journal of Endocrinological Investigation · 2025
DOI 10.1007/s40618-025-02700-7
narrative_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg once weekly significantly reduces major adverse cardiovascular events (MACE) and all-cause mortality in individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD), regardless of diabetes status.Strong
- Tirzepatide 15 mg once weekly is preferred for individuals with obesity and prediabetes when greater weight loss is needed, achieving a 94% risk reduction in diabetes progression over 72 weeks.Strong
- Tirzepatide 15 mg once weekly is preferred for individuals with obesity and heart failure with preserved ejection fraction (HFpEF) to improve symptoms and functional capacity, irrespective of glycemic status or weight loss magnitude.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →